tiprankstipranks
Trending News
More News >
Newamsterdam Pharma Company N.V. (NAMS)
:NAMS
US Market
Advertisement

NewAmsterdam Pharma Company (NAMS) Ownership - Who Owns NewAmsterdam Pharma Company?

Compare
212 Followers

NewAmsterdam Pharma Company (NAMS) Ownership Overview

16.40%12.72%2.74%0.92%67.23%
16.40% Insiders
2.74% Other Institutional Investors
0.92% ETFs
67.23% Public Companies and
Individual Investors
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 16.37% of the company’s stock is owned by Institutional Investors, 16.40% is owned by Insiders, and 67.23% is owned by Public Companies and Individual Investors.
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 15.45% of the company’s stock is owned by Institutional Investors, 16.40% is owned by Insiders, and 0.92% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 27, 2025
xxxxxxxxxxxxx
$205567
Aug 25, 2025
xxxxxxxxxxxxx
$2471640
Aug 13, 2025
xxxxxxxxxxxxx
$11290
Jun 26, 2025
xxxxxxxxxxxxx
$69451

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$15070689
Jun 30, 2025
xxxxxxxxxxxxx
$27742238
Jun 30, 2025
xxxxxxxxxxxxx
$34358237
Jun 30, 2025
xxxxxxxxxxxxx
$92649908

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,656,172Insider9.46%267,150,232
10,138,938Institution9.00%254,183,176
6,978,534Institution6.20%174,951,847
6,827,604Insider6.06%171,168,032
6,648,847Institution5.90%166,686,594
5,115,953Institution4.54%128,256,942
2,156,406Institution1.91%54,061,098
1,897,197Institution1.68%47,562,729
1,531,874Institution1.36%38,404,081
838,905Institution0.74%21,031,348

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
6,648,847Institution5.90%166,686,594
2,156,406Institution1.91%54,061,098
838,905Institution0.74%21,031,348
777,280Institution0.69%19,486,410
715,474Institution0.64%17,936,933
653,206Institution0.58%16,375,874
651,100Institution0.58%16,323,077
573,596Institution0.51%14,380,052
473,949Institution0.42%11,881,901
453,541Institution0.40%11,370,273

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
385,153Institution0.34%9,655,786
135,832Institution0.12%2,962,496
125,923Institution0.11%3,156,890
65,295Institution0.06%1,681,999
53,699Institution0.05%1,346,234
44,799Institution0.04%1,127,591
32,477Institution0.03%817,446
31,229Institution0.03%565,557
22,964Institution0.02%578,004
18,719Institution0.02%471,157

FAQ

Who Owns Newamsterdam Pharma Company N.V. (NAMS)?
According to the latest TipRanks data, approximately 2.74% of the company's stock is held by institutional investors, 16.40% is held by insiders, and 67.23% is held by retail investors.
    What percentage of Newamsterdam Pharma Company N.V. (NAMS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.74% of Newamsterdam Pharma Company N.V. (NAMS) stock is held by institutional investors.
      What percentage of Newamsterdam Pharma Company N.V. (NAMS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 67.23% of Newamsterdam Pharma Company N.V. (NAMS) stock is held by retail investors.
        Who owns the most shares of Newamsterdam Pharma Company N.V. (NAMS)?
        ForGrowth NAP B.V. owns the most shares of Newamsterdam Pharma Company N.V. (NAMS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis